Update on Imaging in Chronic Kidney Disease-mineral and Bone Disorder: Promising Role of Functional Imaging

Overview

Journal Skeletal Radiol

Specialties Orthopedics
Radiology

Date 2021 Sep 15

PMID 34524489

Authors

Sharjeel Usmani

Najeeb Ahmed

Gopinath Gnanasegaran

Fahad Marafi

Tim Van den Wyngaert

Affiliations

Soon will be listed here.

Abstract

Disorders of mineral metabolism and bone disease are common complications in chronic kidney disease (CKD) patients and are associated with increased morbidity and mortality. Bone biopsies, bone scintigraphy, biochemical markers, and plain films have been used to assess bone disorders and bone turnover. Of these, functional imaging is less invasive than bone/marrow sampling, more specific than serum markers and is therefore ideally placed to assess total skeletal metabolism. F-sodium fluoride (NaF) PET/CT is an excellent bone-seeking agent superior to conventional bone scan in CKD patients due to its high bone uptake, rapid single-pass extraction, and minimal binding to serum proteins. Due to these properties, F-NaF can better assess the skeletal metabolism on primary diagnosis and following treatment in CKD patients. With the increased accessibility of PET scanners, it is likely that PET scanning with bone-specific tracers such as F-NaF will be used more regularly for clinical assessment and quantitation of bone kinetics. This article describes the pattern of scintigraphic/functional appearances secondary to musculoskeletal alterations that might occur in patients with CKD.

References

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B . Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(9888):260-72. DOI: 10.1016/S0140-6736(13)60687-X. View

Sidibe A, Moore L, Jean S, Mac-Way F . Fracture risk in dialysis and kidney transplanted patients: a protocol for systematic review and meta-analysis. Syst Rev. 2017; 6(1):37. PMC: 5320734. DOI: 10.1186/s13643-017-0416-8. View

Butler A, Olshan A, Kshirsagar A, Edwards J, Nielsen M, Wheeler S . Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009. Am J Kidney Dis. 2015; 65(5):763-72. PMC: 4924349. DOI: 10.1053/j.ajkd.2014.12.013. View

Vajdic C, McDonald S, McCredie M, van Leeuwen M, Stewart J, Law M . Cancer incidence before and after kidney transplantation. JAMA. 2006; 296(23):2823-31. DOI: 10.1001/jama.296.23.2823. View

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K . Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69(11):1945-53. DOI: 10.1038/sj.ki.5000414. View

Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M . Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002; 91(1):103-11. DOI: 10.1159/000057611. View

Davenport M, Perazella M, Yee J, Dillman J, Fine D, McDonald R . Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020; 294(3):660-668. DOI: 10.1148/radiol.2019192094. View

Malluche H, Monier-Faugere M . Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl. 1992; 38:S62-7. View

Evenepoel P, Cavalier E, DHaese P . Biomarkers Predicting Bone Turnover in the Setting of CKD. Curr Osteoporos Rep. 2017; 15(3):178-186. DOI: 10.1007/s11914-017-0362-3. View

10.

Pelletier S, Dubourg L, Carlier M, Hadj-Aissa A, Fouque D . The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013; 8(5):819-23. PMC: 3641616. DOI: 10.2215/CJN.07670712. View

11.

Smith E . The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol. 2014; 9(7):1283-303. PMC: 4078965. DOI: 10.2215/CJN.10941013. View

12.

Fliser D, Kollerits B, Neyer U, Ankerst D, Lhotta K, Lingenhel A . Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18(9):2600-8. DOI: 10.1681/ASN.2006080936. View

13.

Nakatani T, Sarraj B, Ohnishi M, Densmore M, Taguchi T, Goetz R . In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J. 2008; 23(2):433-41. PMC: 2630784. DOI: 10.1096/fj.08-114397. View

14.

Zou D, Wu W, He Y, Ma S, Gao J . The role of klotho in chronic kidney disease. BMC Nephrol. 2018; 19(1):285. PMC: 6198535. DOI: 10.1186/s12882-018-1094-z. View

15.

Malluche H, Monier-Faugere M . Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 2006; 65(4):235-42. DOI: 10.5414/cnp65235. View

17.

Joy M, Karagiannis P, Peyerl F . Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007; 13(5):397-411. PMC: 10437388. DOI: 10.18553/jmcp.2007.13.5.397. View

18.

Sherrard D, Hercz G, Pei Y, Maloney N, Greenwood C, Manuel A . The spectrum of bone disease in end-stage renal failure--an evolving disorder. Kidney Int. 1993; 43(2):436-42. DOI: 10.1038/ki.1993.64. View

19.

Rocha L, Higa A, Barreto F, Dos Reis L, Jorgetti V, Draibe S . Variant of adynamic bone disease in hemodialysis patients: fact or fiction?. Am J Kidney Dis. 2006; 48(3):430-6. DOI: 10.1053/j.ajkd.2006.05.028. View

20.

Andress D . Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008; 73(12):1345-54. DOI: 10.1038/ki.2008.60. View

21.

Sprague S, Bellorin-Font E, Jorgetti V, Carvalho A, Malluche H, Ferreira A . Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2015; 67(4):559-66. DOI: 10.1053/j.ajkd.2015.06.023. View